Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 25, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on November 23, 2005:
- Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("GSK Trust"), transferred 9,601 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- The Company was advised of these transactions on November 24, 2005.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold interests in the shares held by the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust to assess the impact of the 9,601 share transfer.
- Confirm the specific allocation of shares to individual participants under the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full Disclosure Rule 3.1.4R (1) (b) requirements to ensure complete compliance regarding the directors' interests.